Sector Gamma AS boosted its position in shares of Qiagen NV (NYSE:QGEN) by 14.4% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 484,601 shares of the company’s stock after acquiring an additional 61,100 shares during the quarter. Qiagen comprises about 2.7% of Sector Gamma AS’s portfolio, making the stock its 13th largest position. Sector Gamma AS owned about 0.21% of Qiagen worth $15,977,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of QGEN. Vanguard Group Inc. raised its stake in shares of Qiagen by 3.0% during the 2nd quarter. Vanguard Group Inc. now owns 7,070,710 shares of the company’s stock valued at $286,718,000 after buying an additional 206,294 shares during the last quarter. D. E. Shaw & Co. Inc. raised its stake in shares of Qiagen by 28.6% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 2,195,033 shares of the company’s stock valued at $89,011,000 after buying an additional 487,844 shares during the last quarter. Waddell & Reed Financial Inc. raised its stake in shares of Qiagen by 134.5% during the 2nd quarter. Waddell & Reed Financial Inc. now owns 1,913,610 shares of the company’s stock valued at $77,597,000 after buying an additional 1,097,432 shares during the last quarter. Invesco Ltd. raised its stake in shares of Qiagen by 199.7% during the 2nd quarter. Invesco Ltd. now owns 1,821,967 shares of the company’s stock valued at $73,880,000 after buying an additional 1,213,968 shares during the last quarter. Finally, Sycomore Asset Management raised its stake in shares of Qiagen by 103.5% during the 3rd quarter. Sycomore Asset Management now owns 1,410,503 shares of the company’s stock valued at $38,345,000 after buying an additional 717,320 shares during the last quarter. 62.19% of the stock is owned by institutional investors.
Shares of Qiagen stock traded up $0.30 on Friday, hitting $31.61. The company’s stock had a trading volume of 1,132,065 shares, compared to its average volume of 1,277,807. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.18 and a current ratio of 2.45. Qiagen NV has a 1 year low of $25.04 and a 1 year high of $41.55. The firm has a fifty day moving average price of $30.20 and a 200-day moving average price of $35.78. The company has a market capitalization of $6.83 billion, a price-to-earnings ratio of 23.59, a price-to-earnings-growth ratio of 2.26 and a beta of 0.83.
Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.36 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.35 by $0.01. Qiagen had a positive return on equity of 12.24% and a negative net margin of 1.68%. The firm had revenue of $382.70 million during the quarter, compared to analyst estimates of $382.98 million. During the same quarter in the previous year, the business earned $0.35 EPS. Qiagen’s revenue for the quarter was up 1.3% compared to the same quarter last year. As a group, analysts forecast that Qiagen NV will post 1.4 EPS for the current year.
QGEN has been the subject of a number of recent research reports. TheStreet lowered Qiagen from a “b-” rating to a “c+” rating in a research note on Friday, October 18th. Wolfe Research upgraded Qiagen from a “peer perform” rating to an “outperform” rating in a research note on Thursday, October 17th. Barclays lowered Qiagen from an “overweight” rating to an “equal weight” rating and set a $32.00 price objective for the company. in a research note on Tuesday, October 8th. Kepler Capital Markets lowered Qiagen from a “hold” rating to a “reduce” rating in a research note on Wednesday, October 9th. Finally, Piper Jaffray Companies cut their price target on Qiagen from $36.00 to $31.00 and set a “neutral” rating for the company in a research note on Tuesday, October 8th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $33.57.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Featured Story: Stocks at 52 Week High
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.